Clomipramine Treatment of Agoraphobic Women

Johnston, David G.; Troyer, Iris E.; Whitsett, Stan F.

doi:10.1001/archpsyc.1988.01800290073009

Cited by 66 publications

(14 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Modigh, Westberg and Eriksson (1992) suggest that clomipramine may be effective at lower doses than those used in their trial. This would be in agreement with the clinical experience and with several studies published over the past 10 years, in which the average effective anti-PAG dose of clomipramine was < 100 mg/day (Gloger et al, 1981(Gloger et al, , 1989Gentil, 1986;Johnston, Troyer and Whitsett, 1988). Gloger et al (1991) reported no difference between groups treated with up to 75 mg/day (mean = 41.5) or 100-150 mg/day of clomipramine.…”

Section: Introductionsupporting

confidence: 89%

“…However, this should not have favoured clomipramine, as its mean final dose was lower than that attained by Johnston, Troyer and Whitsett (1988), although similar to the lower dose group reported by Gloger et al (1991). Accordingly, the mean final dose of imipramine was within the range considered effective in the dose-response study of Mavissakalian and Perel (1989) and Modigh, Westberg and Eriksson (1992).…”

Section: Discussionsupporting

confidence: 62%

“…We recently documented continued improvements in psychological functioning associated with prolonged remissions (Ito et al, submitted). The present trial was designed to assess only comparative acute efficacy, in the fashion of the standards of the PAG literature (Ballenger et al, 1988;Johnston, Troyer and Whitsett, 1988). If relapse is to be taken as a measure of effectiveness, a specific discontinuation study after prolonged treatment is required.…”

Section: Discussionmentioning

confidence: 99%

“…This was confirmed by double-blind controlled trials against placebo (Johnston, Troyer and Whitsett, 1988), 5-hydroxytryptophan and alprazolam (Gloger et al, 1991). We are aware of only two studies comparing clomipramine and imipramine in PAG.…”

Section: Introductionmentioning

confidence: 86%

See 3 more Smart Citations

Clomipramine, a better reference drug for panic/agoraphobia. I. Effectiveness comparison with imipramine

Gentil¹,

Lotufo-Neto

Andrade

et al. 1993

J Psychopharmacol

View full text Add to dashboard Cite

An 8-week, double-blind, flexible-dose trial comparing low doses of clomipramine (mean=50 mg) with moderate doses of imipramine (mean=113.8 mg and propanteline (active placebo), was carried out in 60 out-patients with panic disorder with or without agoraphobia. Efficacy evaluation included global, anxiety and depression rating scales, and the determination of rates of relapse over up to 10 weeks of single-blind placebo follow-up. Both tricyclics were significantly more effective than propanteline, but clomipramine tended to act faster and more consistently than imipramine on most measures. Given the degree of blindness achieved and the significantly lower doses of clomipramine, this seems a better reference drug than imipramine for clinical trials in panic/agoraphobia.

show abstract

Section: Introductionsupporting

confidence: 89%

Section: Discussionsupporting

confidence: 62%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 86%

See 2 more Smart Citations

Clomipramine, a better reference drug for panic/agoraphobia. I. Effectiveness comparison with imipramine

Gentil¹,

Lotufo-Neto

Andrade

et al. 1993

J Psychopharmacol

View full text Add to dashboard Cite

show abstract

“…In a 26-week long-term study, it was as effective as fluoxetine (Amore et al 1999a) (A). Á Clomipramine also showed efficacy in DBPC Johnston et al 1988) and comparator-controlled studies (Cassano et al 1988;Fahy et al 1992;Modigh et al 1992;Wade et al 1997).…”

Section: Tricyclic Antidepressants (Tcas) Treatment Withmentioning

confidence: 98%

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Bandelow

Zohar

Hollander

et al. 2008

The World Journal of Biological Psychiatry

711

410

View full text Add to dashboard Cite

In this report, which is an update of a guideline published in 2002 (Bandelow et al. 2002, recommendations for the pharmacological treatment of anxiety disorder, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) are presented. Since the publication of the first version of this guideline, a substantial number of new randomized controlled studies of anxiolytics have been published. In particular, more relapse prevention studies are now available that show sustained efficacy of anxiolytic drugs. The recommendations, developed by the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders, a consensus panel of 30 international experts, are now based on 510 published randomized, placebo-or comparator-controlled clinical studies (RCTs) and 130 open studies and case reports. First-line treatments for these disorders are selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs) and the calcium channel modulator pregabalin. Tricyclic antidepressants (TCAs) are equally effective for some disorders, but many are less well tolerated than the SSRIs/ SNRIs. In treatment-resistant cases, benzodiazepines may be used when the patient does not have a history of substance abuse disorders. Potential treatment options for patients unresponsive to standard treatments are described in this overview. Although these guidelines focus on medications, non-pharmacological were also considered. Cognitive behavioural therapy (CBT) and other variants of behaviour therapy have been sufficiently investigated in controlled studies in patients with anxiety disorders, OCD, and PTSD to support them being recommended either alone or in combination with the above medicines.

show abstract

Specificity of Serotonin Reuptake Inhibitors in the Treatment of Obsessive-Compulsive Disorder

Goodman¹

1990

Arch Gen Psychiatry

288

View full text Add to dashboard Cite

Clomipramine Treatment of Agoraphobic Women

Cited by 66 publications

References 29 publications

Clomipramine, a better reference drug for panic/agoraphobia. I. Effectiveness comparison with imipramine

Clomipramine, a better reference drug for panic/agoraphobia. I. Effectiveness comparison with imipramine

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Specificity of Serotonin Reuptake Inhibitors in the Treatment of Obsessive-Compulsive Disorder

Contact Info

Product

Resources

About